▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #846 by analyst upside · 2026-11-13
SGMT
Sagimet Biosciences Inc.
Healthcare · Market Cap $775M · P/E 0x
ANALYST PRICE TARGET
+155.3%
implied upside to consensus target
Current Price $10.93
Consensus Target $27.91
Bull Target $56.0
Bear Target $7.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
8
Hold
0
Sell
1
52-Week Low $4.5
52-Week High $11.45
YTD Return +82.5%
FUNDAMENTALS
Market Cap $775M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.27
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.5
52-Week High $11.45
Current Price $10.93
Bear Target $7.0
Bull Target $56.0
● Now $10.93 ● Target $27.91
TRADING DATA
Avg Volume 1.3M
YTD Return +82.5%
Analyst Count 11
Consensus Buy
Upside to Target +155.3%
Last Updated 2026-11-13

ANALYST SUMMARY

Sagimet Biosciences Inc. (SGMT) is currently trading at $10.93 with a Wall Street consensus price target of $27.91, implying potential upside of 155.3% over the next 12 months. 11 analysts currently cover SGMT, with a consensus rating of Buy - 91% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $56.0, while the most cautious has a target of $7.0.

SGMT operates in the Healthcare sector with a market capitalisation of $775M. The stock is up 82.5% year-to-date and is currently trading near the upper end of its 52-week range of $4.5 – $11.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ZVRA +126.3%
Zevra Therapeutics, Inc.
$664M · P/E 9.1x · Buy
APMD +202.7%
Apnimed, Inc.
$692M · P/E 2.3x · Buy
MGTX +215.7%
MeiraGTx Holdings plc
$844M · P/E 10.1x · Buy
COLL +79.9%
Collegium Pharmaceutical, Inc.
$775M · P/E 22.9x · Buy
VOR +101.9%
Vor Biopharma Inc.
$1B · P/E 0.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for SGMT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-10-05 31% win rate (48 calls)
Guggenheim - Reiterated
Buy → Buy 2026-10-02 62% win rate (8 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-10-01 14% win rate (7 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2026-10-01 Building track record
Barclays ↑ Upgrade
Equal-Weight → Overweight 2026-09-09 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2026-09-09 40% win rate (10 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-08-25 31% win rate (48 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2026-08-14 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
19/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →